S&P 500   4,145.19
DOW   32,803.47
QQQ   324.34
What to Expect from the Markets in a Recession
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.34
What to Expect from the Markets in a Recession
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.34
What to Expect from the Markets in a Recession
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.34
What to Expect from the Markets in a Recession
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:ALEC

Alector - ALEC Stock Forecast, Price & News

$13.06
0.00 (0.00%)
(As of 08/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$11.17
$13.16
50-Day Range
$7.82
$13.06
52-Week Range
$7.50
$29.30
Volume
48,239 shs
Average Volume
673,185 shs
Market Capitalization
$1.09 billion
P/E Ratio
33.49
Dividend Yield
N/A
Price Target
$20.86

Alector MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
59.7% Upside
$20.86 Price Target
Short Interest
Healthy
9.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.28mentions of Alector in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1,542 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($0.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

82nd out of 1,293 stocks

Biological Products, Except Diagnostic Industry

10th out of 197 stocks

ALEC stock logo

About Alector (NASDAQ:ALEC) Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $13.06 on Monday. The company's 50 day simple moving average is $10.19 and its 200 day simple moving average is $12.10. Alector has a fifty-two week low of $7.50 and a fifty-two week high of $29.30. The firm has a market capitalization of $1.09 billion, a P/E ratio of 33.49 and a beta of 1.08.

Alector (NASDAQ:ALEC - Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.47) by $0.59. Alector had a net margin of 12.06% and a return on equity of 12.16%. Sell-side analysts expect that Alector will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Mizuho assumed coverage on Alector in a research note on Wednesday, July 6th. They issued a "buy" rating and a $15.00 price target on the stock. Citigroup reduced their price target on shares of Alector from $34.00 to $19.00 and set a "buy" rating for the company in a research report on Monday, July 11th. Barclays cut their price objective on Alector from $42.00 to $14.00 in a research report on Wednesday, May 11th. Finally, The Goldman Sachs Group lowered their price objective on shares of Alector from $9.00 to $6.00 and set a "sell" rating for the company in a research note on Tuesday, May 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Alector has an average rating of "Moderate Buy" and a consensus price target of $20.86.

Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Stock News Headlines

Alector: Q2 Earnings Snapshot
Alector (NASDAQ:ALEC) Shares Up 9.7%
Alector (ALEC) Q2 Earnings and Revenues Beat Estimates
Expert Ratings for Alector
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Company Calendar

Last Earnings
8/04/2022
Today
8/08/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
208
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.86
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+59.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-36,330,000.00
Pretax Margin
12.65%

Debt

Sales & Book Value

Annual Sales
$207.09 million
Book Value
$3.70 per share

Miscellaneous

Free Float
72,586,000
Market Cap
$1.09 billion
Optionable
Not Optionable
Beta
1.08

Key Executives

  • Dr. Tillman Ulf Gerngross Ph.D. (Age 58)
    Co-Founder & Chairman
    Comp: $60k
  • Dr. Arnon Rosenthal Ph.D. (Age 66)
    Co-Founder, CEO & Director
    Comp: $972.75k
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 54)
    Pres and Head of R&D
    Comp: $552.78k
  • Mr. Calvin Yu (Age 46)
    VP of Fin.
    Comp: $519.69k
  • Dr. Robert S. King (Age 59)
    Chief Devel. Officer
    Comp: $658.84k
  • Dr. Marc Grasso M.D. (Age 48)
    Chief Financial Officer
  • Michelle Corral
    VP of Communications & Investor Relations
  • Ms. Danielle Pasqualone J.D.
    Ph.D., Interim Gen. Counsel
  • Erica Jefferson
    VP of Communications & Public Affairs
  • Ms. Clare Hunt M.B.A.
    Head of People













ALEC Stock - Frequently Asked Questions

Should I buy or sell Alector stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alector stock.
View analyst ratings for Alector
or view top-rated stocks.

What is Alector's stock price forecast for 2022?

6 equities research analysts have issued 12 month price objectives for Alector's shares. Their ALEC stock forecasts range from $6.00 to $41.00. On average, they anticipate Alector's stock price to reach $20.86 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts' price targets for Alector
or view top-rated stocks among Wall Street analysts.

How has Alector's stock performed in 2022?

Alector's stock was trading at $20.65 at the beginning of the year. Since then, ALEC shares have decreased by 36.8% and is now trading at $13.06.
View the best growth stocks for 2022 here
.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Alector
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) released its quarterly earnings data on Thursday, August, 4th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.59. Alector had a trailing twelve-month return on equity of 12.03% and a net margin of 12.06%.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by a number of institutional and retail investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (0.22%), Strs Ohio (0.08%), Russell Investments Group Ltd. (0.07%), Truist Financial Corp (0.06%), TD Asset Management Inc. (0.05%) and SG Americas Securities LLC (0.05%). Company insiders that own Alector stock include Arnon Rosenthal, Calvin Yu, David M Wehner, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Sabah Oney, Shehnaaz Suliman and Terrance Mcguire.
View institutional ownership trends for Alector
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $13.06.

How much money does Alector make?

Alector (NASDAQ:ALEC) has a market capitalization of $1.09 billion and generates $207.09 million in revenue each year. The company earns $-36,330,000.00 in net income (profit) each year or $0.39 on an earnings per share basis.

How many employees does Alector have?

Alector employs 208 workers across the globe.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.

This page (NASDAQ:ALEC) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.